e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that its shares will cease to trade on the OTCQX Best Market in the US from December 31, due to limited trading since they began trading on the platform on September 24, 2021. Explains that "the expenses associated with the company's ordinary shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders".
e-Therapeutics ordinary shares will continue to be admitted to trading on AIM as the company's primary market.
Current stock price: 8.07 pence
12-month change: down 53%
By Holly Beveridge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.


(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.


(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...


e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was